• Reid, Gregor

    Investigator, Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital
    Assistant Professor, Division of Hematology, Oncology and BMT, Department of Pediatrics, Faculty of Medicine, University of British Columbia
    Scientist, Michael Cuccione Childhood Cancer Research Program
    Degrees / Designations
    B.Sc., PhD
    Primary Area of Research
    Childhood Diseases
    Secondary Area(s) of Research
    604-875-2000 ext. 4692
    Lab Phone
    Mailing Address
    BC Children's Hospital
    Room A5-162
    950 West 28th Avenue
    Vancouver, BC V6Z 4H4
    Affiliate Websites
    Research Areas
    Tumour immunology
    The central idea of my research is that appropriate stimulation of the immune system will provide an effective strategy for the treatment and prevention of childhood cancers. Our research, therefore, seeks to understand the influence of the immune system during cancer progression and to use this knowledge to develop approaches to induce therapeutic anti-cancer immune activity. In addition to evaluating the impact of immune responses on established disease, our research seeks to identify the influence of the immune system before cancer is detected. To achieve these goals we use a range of experimental systems, including transgenic mice, adoptive transfer models, human xenograft models, and ex vivo and in vitro analysis of patient samples and human cell lines. It is hoped this broad approach will expedite the development of effective new treatments for children with cancer.
    Current Projects

    1. Immune therapy for acute lymphoblastic leukemia (ALL). This research addresses the issue of ALL immunogenicity and the induction of anti-ALL immune activity as a strategy to eradicate residual disease after chemotherapy. Our work has described the ability of immunostimulatory DNA (CpG ODN) treatment both to enhance the immunogenicity of primary human ALL blasts and to stimulate significant anti-ALL immune activity resulting in T cell-mediated protection against disease progression. This work provided the first report of immune-mediated killing of primary human ALL in vivo in the absence of adoptive transfer of lymphocytes or stem cell transplantation, and indicates that toll-like receptor signaling may provide a clinically feasible strategy for augmenting immune responses against ALL. A clinical trial based on this approach is aboout to commence. The next major step in our development of CpG ODN as an immune therapy for ALL will involve the examination of their ability to induce anti-leukemia immune activity after chemotherapy in a spontaneous mouse model of ALL, and to generate ALL-specific T cells against autologous leukemia blasts from patients. By using such models, in which immune tolerance must be overcome, this ongoing work will be the most stringent pre-clinical testing yet of an immune therapy for pediatric leukemia. The goal of these studies is to provide insights that will optimize the clinical application of this approach.

    2. Immune influence on ALL development. Infection has long been postulated to play a role in the progression of childhood ALL. Using novel models of this disease we are actively identifying the influence of the immune system during a pre-leukemic state on the onset of ALL. Our research indicates that the immune system may exert considerable control over early pre-leukemic cell expansion, but other mechanisms, such as growth factor availability, may also be important. Our long-term goal is to identify the growth constraints on pre-leukemic expansion, understand the influence of infection on these constraints, and use this knowledge to develop targeted strategies to reduce the incidence of primary disease and relapse.

    Selected Publications

    Seif AE, Barrett D, Milone M, Brown VI, Grupp SA and Reid GS. 2009. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood. 114(12):2459-66. PMID: 19636062

    Reid GS, Shan X, Coughlin CM, Lassoued W, Pawel BR, Wexler LH, Thiele CJ, Tsokos M, Pinkus JL, Pinkus GS, Grupp SA, Vonderheide RH. 2009. Interferon-gamma-mediated restoration of T cell infiltration into neuroblastoma tumors in vivo. Clin Cancer Res 15(21):6602-8 PMID: 19825945

    Barbaric D, Corthals SL, Jastaniah WA, Asalanian S, Shimizu H, Reid GS, Schultz KR. 2008 Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission. Br J Haematol. 141(2):271-3. PMID: 18307567

    Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K and Reid GSD. (2006) Differential immune effects mediated by TLR stimulation in precursor-B cell acute lymphoblastic leukaemia. Brit J Haem. 132(4):452-458. (PMID 16412017)

    Fujii H, Trudeau JD, Teachey DT, Fish JD, Grupp SA, Schultz KR, and Reid GSD. (2007) In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood. 109(5):2008-13. (PMID 17068155)

    Reid GSD, She K, Terrett L, Food MR, Trudeau JD and Schultz KR. (2005) CpG stimulation of precursor B lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells towards a Th1 response. Blood. 105(9): 3641-7. (PMID 15650062)

    Barbaric D, Wynne K, Aslanian S, Bond M, and Reid GSD. (2005) Immune Evasion Strategies of Pediatric Precursor-B Acute Lymphoblastic Leukemia after Allogeneic Bone Marrow Transplantation – a Case Study. Leuk Res. 29(6):711-4. (PMID 15863213)

    Kariminia A, Ivison SM, Leung VM, Sung S, Couto N, Rozmus J, Rolf N, Narendran A, Dunn SE, Reid GS, Schultz KRY-box- binding protein 1 contributes to IL- 7 mediated survival signaling in B- cell precursor acute lymphoblastic leukemia. Oncol Lett. 2017 Jan;13 PMID: 28123588 Impact Factor: 1.42. 

    • Canadian Cancer Society Career Development Award in Prevention, Junior Faculty Award - Project: "Immune-mediated prevention of pediatric acute lymphoblastic leukemia." (2013-2016)
    • CIHR Operating Grant – Project: "Identifying determinants of acute lymphoblastic leukemia progression" (2013-2018)
    • Leukemia & Lymphoma Society of Canada
    • Cancer Prevention Foundation
    • WES Foundation
    Honours & Awards
    Research Group Members